Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Yubo International Biotech Limited (YBGJ : OTC)

• Company Description    MAGNA-LAB INC. is a development stage company. Co. has developed and now markets and intends to produce the MAGNA-SLn, the first of Co.'s proposed series of anatomy specific MRI (Magnetic Resonance Imaging) products which are smaller and cost less to own, install and operate than present ``whole body`` MRI systems. Number of Employees: 20

• Price / Volume Information    Yesterday's Closing Price: $0.07 Daily Weekly Monthly 20 Day Moving Average: 271 shares Shares Outstanding: 118.18 (millions) Market Capitalization: $8.30 (millions) Beta: 6.84 52 Week High: $1.10 52 Week Low: $0.07 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -38.31% -30.53% 12 Week -75.89% -73.50% Year To Date -83.16% -58.97%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Room 105 Building 5 31 Xishiku Avenue - Beijing,F4 10036 CHN ph: 86-010-6615-5141 fax: 516-595-1159 None http://www.yubogroup.com

• General Corporate Information    Officers Jun Wang - Chief Executive Officer; President and Director Lina Liu - Chief Financial Officer; Treasurer and Director Yang Wang - Director Zhihui Bai - Director Seymour Kessler - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 988366100 SIC: 3845 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/21 Next Expected EPS Date: - Share - Related Items Shares Outstanding: 118.18 Most Recent Split Date: 3.00 (0.01:1) Beta: 6.84 Market Capitalization: $8.30 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 10.40 EPS Growth vs. Year Ago Period: -100.00% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -96.71% vs. Previous Quarter: -95.43% ROE 03/31/22 - - 12/31/21 - -388.46 09/30/21 - -162.24 ROA 03/31/22 - -38.26 12/31/21 - -36.23 09/30/21 - -31.47 Current Ratio 03/31/22 - 0.27 12/31/21 - 0.38 09/30/21 - 0.53 Quick Ratio 03/31/22 - - 12/31/21 - 0.32 09/30/21 - 0.41 Operating Margin 03/31/22 - -210.80 12/31/21 - -123.89 09/30/21 - - Net Margin 03/31/22 - -210.80 12/31/21 - -123.89 09/30/21 - - Pre-Tax Margin 03/31/22 - -210.80 12/31/21 - -123.96 09/30/21 - -125.66 Book Value 03/31/22 - -0.01 12/31/21 - 0.00 09/30/21 - 0.00 Inventory Turnover 03/31/22 - 1.43 12/31/21 - 2.34 09/30/21 - 1.98 Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - - 12/31/21 - - 09/30/21 - 0.00

Powered by Zacks Investment Research ©